Special Issue "Signaling Pathways and Immune Checkpoint Regulation in Cancer"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (31 March 2019).
Interests: ALK signalling; Immune checkpoint regulation; mTOR sigalling; AP-1 transcription factors; p53 pathway; Mechanisms of lymphomagenesis; Mechanisms of drug resistance; T-cell lymphomas
Intensive research over the last decades has uncovered the dynamic interactions between cancer cells and host immune cells, namely T-lymphocytes, NK cells, dendritic cells and histiocytes. The immune checkpoint plays a crucial role in the immune response against tumor cells, and therefore, better understanding of the underlying mechanisms led to the development of novel immunotherapeutic approaches in cancer. The basic concept of immunotherapy is that the target molecule is on the immune cell and not on the tumor cell, and therefore the same strategy would work on many different cancer cell types with different phenotype and genetic backgrounds. Immune checkpoint therapy initially focused on CTLA-4 with promising results. More recently, the PD-1 (programmed death-1) and its ligand (PD-L1) have been targeted with anti-PD-1 and anti-PD-L1 antibodies, which are currently being tested in clinical trials in a variety of cancers with clinical success. In certain tumor types, immunotherapy efficiency has been associated with PD-L1 protein levels. PD-L1 expression can be regulated at the genetic (e.g. PD-L1 gene amplification), transcriptional and post-translational level, however, the exact mechanisms may be cell type-specific and they are still under investigation. Transcription factors, known to regulate PD-L1 gene expression, commonly operate as targets of known oncogenic signaling pathways, thus providing the biologic rationale for combination treatment strategies such as immunotherapy with targeted therapy.
This Special Issue focuses on the mechanisms of immune checkpoint regulation by oncogenic signaling pathways that may represent novel therapeutic targets, as well as the role of the tumor microenvironment. In addition, immunotherapy-related studies including PD-1/PD-L1 antibodies and CART-T cell therapy are most welcome for publication consideration in this issue.
Prof. Dr. Georgios Rassidakis
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- signaling pathways
- immune checkpoint regulation
- CART-T cell therapy
- targeted therapy
- transcription factors